HaroldN.KeerMDPhD

Oncology • Stanford, CA

Genitourinary Oncology, Hematologic Oncology

Chief Medical Officer, Taiho Oncology, Inc.

Join to view full profile

Dr. Keer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Keer's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Summary

Oncologist leading R& D efforts at Taiho Oncology, Inc. as Chief Medical Officer

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1994 - 1997
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1993
Northwestern University The Feinberg School of MedicineClass of 1990

Certifications & Licensure

CA State Medical License 2002 - 2026

Clinical Trials

Guadecitabine Extension Study Start of enrollment: 2018 Jul 18
Terminated
Phase 2
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Start of enrollment: 2019 Sep 30
Enrolling by invitation
Phase 2

Publications & Presentations

PubMed

25 citations
A Phase 1 Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults With Advanced Cancers or Lymphoma.
Monica M. Mita, Patricia LoRusso, Kyriakos P. Papadopoulos, Michael S. Gordon, Alain C. Mita
Clinical Cancer Research. 2020-01-03
9 citations
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised...
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan
The Lancet. Haematology. 2024-01-01
8 citations
Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients.
Ekaterina Jahn, Maral Saadati, Pierre Fenaux, Marco Gobbi, Gail J Roboz
Leukemia. 2023-11-01

Abstracts/Posters

Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
Harold N. Keer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Astex Announces That the Phase 3 ASCERTAIN - Acute Myeloid Leukemia (AML) Clinical Study of Oral Hypomethylating Agent Decitabine and Cedazuridine Fixed-Dose Combination (ASTX727 or DEC-C) Met the Trial’s Primary EndpointMay 12th, 2022